Aeon biopharma announces preliminary top-line results from phase 2 interim analysis of abp-450 in the preventive treatment of chronic migraine

Irvine, calif., may 03, 2024 (globe newswire) -- aeon biopharma, inc. (“aeon” or the “company”) (nyse: aeon), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that the preliminary top-line results from its planned interim analysis of the phase 2 trial with abp-450 in the preventive treatment for chronic migraine did not meet the primary endpoint.
AEON Ratings Summary
AEON Quant Ranking